Change of Surfactant Protein D and A After Renal Ischemia Reperfusion Injury
Overview
Affiliations
Acute kidney injury (AKI) is associated with widespread effects on distant organs, including the lungs. Surfactant protein (SP)-A and SP-D are members of the C-type lectin family, which plays a critical role in host defense and regulation of inflammation in a variety of infections. Serum levels of SP-A and SP-D are markers to reflect lung injury in acute respiratory distress syndrome, idiopathic pulmonary fibrosis, and sarcoidosis. We investigated the change of lung-specific markers, including SP-A and SP-D in an AKI mice model. We studied C57BL/6J mice 4 and 24 hours after an episode of ischemic AKI (23 min of renal pedicle clamping and then reperfusion); numerous derangements were present, including SP-A, SP-D, and lung tight-junction protein. Neutrophil infiltration and apoptosis in the lungs increased in ischemic AKI. Receptor for advanced glycation end products (RAGE) in the lungs, a marker of pneumocyte I, was not changed. Lung tight-junction proteins, particularly claudin-4, claudin-18, and anti-junctional adhesion molecule 1 (JAMA-1), were reduced in 24 hours after AKI. Serum SP-A and SP-D significantly increased in ischemic AKI. SP-A and SP-D in the lungs did not increase in ischemic AKI. The immunohistochemistry showed that the expression of SP-A and SP-D was intact in ischemic AKI. SP-A and SP-D in the kidneys were significantly higher in AKI than in the sham. These patterns of SP-A and SP-D in the kidneys were similar to those of serum. AKI induces apoptosis and inflammation in the lungs. Serum SP-A and SP-D increased in ischemic AKI, but these could have originated from the kidneys. So serum SP-A and SP-D could not reflect lung injury in AKI. Further study is needed to reveal how a change in lung tight-junction protein could influence the prognosis in patients with AKI.
Tight Junctions, the Epithelial Barrier, and Toll-like Receptor-4 During Lung Injury.
Godbole N, Chowdhury A, Chataut N, Awasthi S Inflammation. 2022; 45(6):2142-2162.
PMID: 35779195 PMC: 9649847. DOI: 10.1007/s10753-022-01708-y.
von Knethen A, Heinicke U, Laux V, Parnham M, Steinbicker A, Zacharowski K Biomedicines. 2022; 10(1).
PMID: 35052778 PMC: 8773193. DOI: 10.3390/biomedicines10010098.
[A review on the effect of Claudin-18 on bronchopulmonary dysplasia in preterm infants].
Zuo J, Tong Y, Yue D Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(5):542-547.
PMID: 34020748 PMC: 8140329.
Hong Y, Jung S, Yang K, Im D, Jeong K, Park C Int J Mol Sci. 2020; 21(10).
PMID: 32438631 PMC: 7279043. DOI: 10.3390/ijms21103583.